Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Receivables: 2019-2024

Historic Receivables for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $972,000.

  • Silence Therapeutics' Receivables fell 92.52% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $28,000, marking a year-over-year decrease of 92.52%. This contributed to the annual value of $972,000 for FY2024, which is 235.17% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Receivables is $972,000, which was up 235.17% from $290,000 recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Receivables registered a high of $37.6 million during FY2020, and its lowest value of $290,000 during FY2023.
  • For the 3-year period, Silence Therapeutics' Receivables averaged around $798,137, with its median value being $972,000 (2024).
  • Its Receivables has fluctuated over the past 5 years, first surged by 94,976.56% in 2020, then plummeted by 98.79% in 2021.
  • Silence Therapeutics' Receivables (MRY) stood at $37.6 million in 2020, then crashed by 98.79% to $455,416 in 2021, then skyrocketed by 148.65% to $1.1 million in 2022, then plummeted by 74.39% to $290,000 in 2023, then surged by 235.17% to $972,000 in 2024.
  • Its last three reported values are $972,000 in FY2024, $290,000 for FY2023, and $1.1 million during FY2022.